BioCentury | Sep 17, 2019
Company News

Sept. 17 Company Quick Takes: Priority Review for Merck Ebola vaccine; plus Edgewise’s debut, Adaptive, AskBio and Acceleron

...NASDAQ:ADPT) and Amgen Inc. (NASDAQ:AMGN) signed a four-year agreement in which Amgen will use Adaptive’s clonoSEQ assay...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

...equity (see “Clever Pegylation Pay Off” ). Broader approval for Adaptive’s clonoSEQ MRD test The clonoSEQ Assay...
...formulation from Aucta Pharmaceuticals (Piscataway, N.J.). Consensus figures provided by FactSet. BioCentury Staff clonoSEQ Assay (Brand), clonoSEQ test (Informal), clonoSEQ Assay...
BioCentury | Jul 31, 2019
Company News

July 31 Company Quick Takes: Bayer, Orion win approval in prostate cancer; plus Keytruda, Roche-Spark, UC v. Broad and more

...upfront payment and is eligible for undisclosed milestones and royalties. BioCentury Staff ADC-1013, JNJ-7107 clonoSEQ Assay (Brand), clonoSEQ test (Informal), clonoSEQ Assay...
BioCentury | Oct 15, 2018
Politics & Policy

FDA guides on minimal residual disease endpoint in hematologic cancer trials

...Disease as Surrogate Endpoint" ). Gottlieb pointed to emerging technologies, such as the newly approved clonoSEQ assay...
BioCentury | Oct 5, 2018
Clinical News

FDA approves minimal residual disease diagnostic

...FDA approved clonoSEQ Assay from Adaptive Biotechnologies Corp. (Seattle, Wash.) to detect minimal residual disease (MRD) in...
...MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma (MM). The agency said clonoSEQ Assay...
...million cells. Adaptive Biotechnologies Corp., Seattle, Wash. Product: clonoSEQ Assay Business: Diagnostic Alicia Parker clonoSEQ Assay (Brand), clonoSEQ test (Informal), clonoSEQ Assay...
BioCentury | Sep 28, 2018
Company News

FDA approves minimal residual disease diagnostic

...FDA approved clonoSEQ Assay from Adaptive Biotechnologies Corp. (Seattle, Wash.) to detect minimal residual disease (MRD) in...
...MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma (MM). The agency said clonoSEQ Assay...
...of detecting MRD at levels below 1 in 1 million cells. Alicia Parker clonoSEQ Assay (Brand), clonoSEQ test (Informal), clonoSEQ Assay...
BioCentury | May 25, 2015
Company News

Multiple Myeloma Research Foundation (MMRF), Amgen, Adaptive Biotechnologies, University of Turin deal

...from Amgen and Revlimid lenalidomide, followed by bone marrow transplant. Adaptive Biotechnologies will provide its clonoSEQ test...
Items per page:
1 - 7 of 7